Skip to main content
. 2022 Mar 31;399(10332):1313–1321. doi: 10.1016/S0140-6736(22)00151-9

Table 2.

Analysis of antibody titre (immunogenicity population)

ZyCoV-D (n=135) Placebo (n=130)
Day 0
GMT (95% CI) 7 (7·00–7·00) 7 (7·00–7·00)
Day 56
GMT (95% CI) 407·58 (266·73–622·83) 57·97 (36·10–93·07)
GMFR (95% CI) 58·23 (38·10–88·98) 8·28 (5·16–13·30)
Day 84
GMT (95% CI) 952·67 (707·94–1282·00) 154·82 (91·25–262·70)
GMFR (95% CI) 136·10 (101·13–183·14) 22·12 (13·04–37·53)

GMT=geometric mean titre. GMFR=geometric mean fold rise.